Browse > Article

Risk Factor Analysis of Clostridium Difficile Associated Diarrhea and Antibiotics Administration  

Oh, Kyung-Sun (Graduate School of Clinical Pharmacy, Sookmyung Women's University)
Lee, Suk-Hyang (Graduate School of Clinical Pharmacy, Sookmyung Women's University)
Publication Information
Korean Journal of Clinical Pharmacy / v.20, no.1, 2010 , pp. 78-84 More about this Journal
Abstract
Background: Clostridium difficile is the primary reason of the nosocomial diarrhea. The antimicrobial therapy plays a central role in the pathogenesis of Clostridium difficile associated diarrhea (CDAD). Although nearly all classes of antimicrobial agents have been associated with CDAD, clindamycin and the third-generation cephalosporins have traditionally been considered to the greatest risk factor. Recent studies have also implicated fluoroquinolones as high-risk agents due to increasing use of the agents. This study was to determine the incidence and the risk factors of CDAD related to the administered antibiotics and to assess the therapeutic regimen of metronidazole or vancomycin based on the C. difficile toxin assay Methods: A retrospective study was performed in patients with Clostridium difficile toxin assay at I Hospital (Incheon, South Korea) during the period from January 2007 through December 2007. Administrative, laboratory, and pharmacy data were collected from Electronic Medical Databases. Results: The analysis included 129 reported C.difficile toxin assay results, with 42 positive cases and 87 negative cases. Significant antibiotic risk factors for CDAD included the use of the fourth-generation cephalosporinse (OR=5.97, 95% CI 1.37-25.98, P=0.017). Administration of metronidazole was protective against CDAD (OR=0.30, 95% CI 0.12-0.74, P=0.009). Prolonged antimicrobial therapy has been associated with an increased risk of CDAD. The third-generation cephalosporins (OR=3.81, 95% CI 1.08-13.41, P=0.037) and aminoglycoside (OR=5.50, 95% CI 1.43-21.10, P=0.013) demonstrated greater risk for CDAD over 15 days than 8days or less days of treatment duration. Conclusions: The fourth and third generation cephalosporin, aminglycoside were the significant risk factors compared with other antibiotics, whereas metronidazole appears to be protective. The longer duration of antiobiotic use increased CDAD.
Keywords
Clostridium difficile associated diarrhea (CDAD); antibiotics;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Dial S, Alrasadi K. et al., Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitor: cohort and case-control studies. CMAJ 2004; 171:33-8.   DOI   ScienceOn
2 Musher DM, Aslam S, Logan N et al., Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40:1586-90.   DOI   ScienceOn
3 Loo VG, Poirier L, Miller MA, et al., A predominantly clonal multi-institutional outbreak of Clostridium difficile associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9.   DOI
4 Maroo S, Lamont JT. Recurrent Clostridium difficile. Gastroenterology 2006; 130:1311-16.   DOI   ScienceOn
5 Chang VT, Nelson K. The role of physical proximity in nosocomial diarrhea. Clin Infect Dis 2000; 31(3):717-22.   DOI   ScienceOn
6 Pepin J, Saheb N, Coulombe MA, et al., Emergence of fluoroquinlones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254-60.   DOI   ScienceOn
7 Gerding DN. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis 2004; 38: 646-8.   DOI   ScienceOn
8 McFarland LV, Clarridge JE, Beneda HW, Rauqi GJ. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a veteran's administration health care system. Clin Infect Dis 2007; 45:114151.
9 McCuster ME, Harris AD, Perencevich E, Roghmann MC. Fluoroquinolone use and Clostrdium difficile-associated diarrhea. Emerging infectious Diseases 2003; 9(6):730-3.   DOI
10 Bricker E, Gag R, Nelson R, et al., Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev CD004610, 2005.
11 Gerding DN, Muto CA, Owens RC. Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46:S32-42.   DOI
12 Bartlett JG. Clinical practices: Antibiotic associated diarrhea. N Engl J Med 2002; 346(5):334-9.   DOI   ScienceOn
13 Gerding DN, Muto CA, Owens RC. Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008; 46:S43-9.   DOI
14 Cleary RK, Grossmann R, Fernandez FB, et al., Metronodazole may inhibit intestinal colonization with Clostridium difficile. Dis Colon Rectum 1998; 41:464-7.   DOI   ScienceOn
15 Kyne L, Hamel MB, Polavarm R, Kelly CP. Health care costs and mortality associated diarrhea with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34:346-53.   DOI   ScienceOn
16 Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonal LC, Fraser VJ. Clostridium difficile associated disease in a setting of Endemicity: identification of novel risk factors. Clin Infect Dis 2007; 45:1543-1549.   DOI   ScienceOn
17 Owens RC. Jr., Donskey CJ, Gaynes RP, Loo VJ, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46:S19-31.   DOI
18 Kelly CP, Pothoulakis C, Lamont JT. Clostridium difficile colitis. N Engl J Med 1994; 330(4):257-62.   DOI   ScienceOn
19 Elliot B, Chang BJ, Golledge CL, Riley TV. Clostridium difficile-associated diarrhea. Internal Medicine Journal 2007; 37:561-568.   DOI   ScienceOn
20 Rice LB. The Maxwell Finland lecture: for the durationrational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile. Clin Infect Dis 2008; 46:491-6.   DOI   ScienceOn